Home World News Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with... World News Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 823 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR As Rates of Some Cancers Increase in Younger People, Researchers Search... May 14, 2025 Doctors Want Breast Cancer Warning Label Put On Cheese October 14, 2019 FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... June 20, 2025 It Might Sound Trite But… May 11, 2021 Load more HOT NEWS Withdrawal of Application to Change the EU Marketing Authorisation for Cervarix Multiple mRNA Vaccines Show Promise for Treating HPV-Related Cancers FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who... Surgical Technique Helps Keep Breast Cancer Patients from Going Under the...
